Amphastar Pharmaceuticals, Inc.
AMPH Nasdaq
SEC CIK 1297184
Follow Amphastar Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$207.6M
+8.2% vs same quarter last year
Net income
$37.8M
+117.7% vs same quarter last year
EPS, diluted
$0.87
+135.1% vs same quarter last year
Operating cash flow
$43.3M
−17.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $719.9M | $98.1M |
| FY24 | $732M | $159.5M |
| FY23 | $644.4M | $137.5M |
| FY22 | $499M | $91.4M |
| FY21 | $437.8M | $62.1M |
| FY20 | $349.8M | $1.4M |
| FY19 | $322.4M | $48.9M |
| FY18 | $294.7M | −$5.7M |
| FY17 | $240.2M | $3.6M |
| FY16 | $255.2M | $9.8M |
| FY15 | $251.5M | −$2.8M |
| FY14 | $210.5M | −$10.7M |
| FY13 | $229.7M | $11.9M |
| FY12 | $204.3M | $18.1M |
| FY11 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 49.5% | 19.5% | 13.6% |
| FY24 | 51.1% | 28.1% | 21.8% |
| FY23 | 54.5% | 30.6% | 21.3% |
| FY22 | 49.9% | 21.5% | 18.3% |
| FY21 | 45.6% | 16% | 14.2% |
| FY20 | 41% | 3.1% | 0.4% |
| FY19 | 40.9% | 0% | 15.2% |
| FY18 | 36.3% | −2.9% | −1.9% |
| FY17 | 37.7% | −0.5% | 1.5% |
| FY16 | 40.8% | 6% | 3.8% |
| FY15 | 30.8% | −2.7% | −1.1% |
| FY14 | 24.4% | −8.5% | −5.1% |
| FY13 | 37.9% | 7.6% | 5.2% |
| FY12 | 44.2% | 12.4% | 8.9% |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $121.2M |
| FY24 | $172.3M |
| FY23 | $145.3M |
| FY22 | $65.1M |
| FY21 | $70.5M |
| FY20 | $23.4M |
| FY19 | $207K |
| FY18 | −$8.6M |
| FY17 | $4.1M |
| FY16 | $17.2M |
| FY15 | −$5.3M |
| FY14 | $553K |
| FY13 | $13.4M |
| FY12 | −$24.8M |
| FY11 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $75.6M |
| FY24 | $85.5M |
| FY23 | $58.1M |
| FY22 | $39.9M |
| FY21 | $28.9M |
| FY20 | $24.4M |
| FY19 | $22.3M |
| FY18 | $25M |
| FY17 | $30.7M |
| FY16 | $9.9M |
| FY15 | $9.9M |
| FY14 | $345K |
| FY13 | $199K |
| FY12 | $811K |
| FY11 | - |
- Amphastar Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Amphastar Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 13.6% | −30.6% |
| FY24 | 21.8% | −47% |
| FY23 | 21.3% | −58% |
| FY22 | 18.3% | −80.4% |
| FY21 | 14.2% | −71.8% |
| FY20 | 0.4% | −62.2% |
| FY19 | 15.2% | −46.2% |
| FY18 | −1.9% | −49.6% |
| FY17 | 1.5% | −45.9% |
| FY16 | 3.8% | −36% |
| FY15 | −1.1% | −37.8% |
| FY14 | −5.1% | −35.5% |
| FY13 | 5.2% | −37.1% |
| FY12 | 8.9% | −29.1% |
| FY11 | - | −27.9% |